Condition: Hepatocellular Carcinoma · Cirrhosis, Liver · Hepatitis B · Sponsor: University of Washington
We are performing a pilot and feasibility randomized controlled trial (RCT) of HCC screening by US + AFP every 6 months (n=100), the current standard-of-care, versus aMRI + AFP every 6 months (n=100) for 12 months (i.e. at time 0, 6 and 12 months) among AI/AN patients with cirrhosis or HBV.
This description comes directly from the study's public registry record.
Jennifer R Harry · 206-616-0397 · jharry@medicine.washington.edu
Stephanie Y Park · 206-744-7050 · sypark22@uw.edu
Always discuss trial participation with your own doctor first.
| Cherokee Nation Health Service | Tahlequah, Oklahoma, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05304234